Endeavor, Medtronic's zotarolimus-eluting stent, has "significant safety advantages" over Boston Scientific's paclitaxel-coated rival Taxus device, researchers say. Three-year results from the ENDEAVOR IV clinical trial were presented yesterday at the Transcatheter Cardiovascular Therapeutics ...
Please Login to read the full article.
